Medicure (OTCMKTS:MCUJF) Posts Earnings Results, Misses Expectations By $0.07 EPS

Medicure (OTCMKTS:MCUJF – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.07), Zacks reports. Medicure had a negative net margin of 23.14% and a negative return on equity of 54.55%.

Medicure Trading Up 1.8%

MCUJF stock opened at $2.56 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.64 and a current ratio of 0.97. Medicure has a 1-year low of $0.67 and a 1-year high of $3.45. The business has a fifty day moving average price of $2.47 and a 200-day moving average price of $1.28.

About Medicure

(Get Free Report)

Medicure Inc. is a Canadian pharmaceutical company focused on developing and commercializing products for cardiovascular disease. Through its U.S. operations, the company markets Aggrastat (tirofiban), an intravenous antiplatelet medicine used to help reduce the risk of certain cardiovascular events in patients with acute coronary syndrome, and Zypitamag (pitavastatin), a medicine for managing elevated cholesterol. The company serves customers in the United States and has historically focused its commercial activities on the U.S. cardiovascular market.

See Also

Earnings History for Medicure (OTCMKTS:MCUJF)

Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.